WO2026133299 - TREATMENT OF NON-CYSTIC FIBROSIS BRONCHIECTASIS (NCFB)
National phase entry is expected:
Publication Number
WO/2026/133299
Publication Date
25.06.2026
International Application No.
PCT/IB2025/063292
International Filing Date
22.12.2025
Title **
[English]
TREATMENT OF NON-CYSTIC FIBROSIS BRONCHIECTASIS (NCFB)
[French]
TRAITEMENT DE LA BRONCHECTASIE NON LIÉE À LA MUCOVISCIDOSE (NCFB)
Applicants **
SPEXIS AUSTRALIA PTY LTD
Inventors
FROEHLICH, Juergen
Priority Data
63/736,624
20.12.2024
US
63/806,037
15.05.2025
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP Australia
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 7302 | |
| EPO | Filing, Examination, Granting | 241643 | |
| Japan | Filing, Examination, Granting | 5610 | |
| South Korea | Filing, Examination, Granting | 15226 | |
| USA | Filing, Examination, Granting | 94140 |
Total:
363,921
Contact Us
Abstract[English]
Described is a method for improving the condition of a patient suffering from Non-Cystic Fibrosis Bronchiectasis (NCFB), comprising administering to the patient by inhalation from 2.5 million international units (MIU) to 6 MIU of colistimethate sodium (CMS) once a day for a period of at least 28 days. Other embodiments are also disclosed.[French]
L'invention concerne une méthode pour améliorer l'état d'un patient souffrant de bronchectasie non liée à la mucoviscidose (NCFB), comprenant l'administration au patient par inhalation de 2,5 millions d'unités internationales (MUI) à 6 MUI de colistiméthate de sodium (CMS) une fois par jour pendant une période d'au moins 28 jours. D'autres modes de réalisation sont également divulgués.